{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:57:01Z","timestamp":1792792621779,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pancreatic metastasis is a rare malignant tumor; when it comes to multiple cancers, it may be a challenge to identify the primary lesion of new pancreatic metastases. With the continuous advancement of imaging technology, the PET\/computed tomography (CT) has been widely used because of its high diagnostic accuracy and non-invasiveness. However, in the present case, the patient had history of limited small-cell lung carcinoma and prostatic cancer; the combined application of the three kinds of PET\/CT was used to identify the new metastases of pancreatic and bone metastases, which suggested a high probability of primary G2 pancreatic neuroendocrine tumor with bone metastases. After the needle biopsy, samples were confirmed by diagnostic pathology as small-cell lung cancer metastasizing to the pancreas and bone. The results of our case suggests the irreplaceability of pathology and possibility of misdiagnosis by PET\/CT; moreover, it also supplements clinical data for second primary cancers after small-cell lung cancer.<\/jats:p>","DOI":"10.3389\/fonc.2024.1403260","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T05:04:29Z","timestamp":1729055069000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Pancreatic metastasis from small-cell lung cancer appears as primary G2 pancreatic neuroendocrine tumor on combined contrast PET imaging with three probes"],"prefix":"10.3389","volume":"14","author":[{"given":"Huimin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenji","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14604","article-title":"Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer","volume":"13","author":"Li","year":"2022","journal-title":"Thorac Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0706","article-title":"The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients: a large population-based study","volume":"14","author":"Cai","year":"2018","journal-title":"Future Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"van Meerbeeck","year":"2011","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07363-x","article-title":"The prevalence and locations of bone metastases using whole-body MRI in treatment-na\u00efve intermediate- and high-risk prostate cancer","volume":"31","author":"Ottosson","year":"2021","journal-title":"Eur Radiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000123981.03084.06","article-title":"Baseline staging of newly diagnosed prostate cancer: a summary of the literature","volume":"171","author":"Abuzallouf","year":"2004","journal-title":"J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga\u2013prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2016.13","article-title":"PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges","volume":"19","author":"Rowe","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1967\/s002449910952","article-title":"More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET\/CT","volume":"22","author":"Pianou","year":"2019","journal-title":"Hell J Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1021\/ar800188e","article-title":"Tumor imaging and therapy using radiolabeled somatostatin analogues","volume":"42","author":"de Jong","year":"2009","journal-title":"Acc Chem Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265622","article-title":"18F-labeled somatostatin analogs as PET tracers for the somatostatin receptor: ready for clinical use","volume":"64","author":"Leupe","year":"2023","journal-title":"J Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.199760","article-title":"Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: A prospective phase II imaging study","volume":"59","author":"Nicolas","year":"2018","journal-title":"J Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2967\/jnumed.119.235093","article-title":"Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET\/CT in patients with metastatic, well-differentiated neuroendocrine tumors: A prospective study","volume":"61","author":"Zhu","year":"2020","journal-title":"J Nucl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2023.108338","article-title":"Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist","author":"Ahenkorah","year":"2023","journal-title":"Nucl Med Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05249-8","article-title":"Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE","volume":"48","author":"Xie","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061486","article-title":"Liver tumor burden in pancreatic neuroendocrine tumors: CT features and texture analysis in the prediction of tumor grade and 18F-FDG uptake","volume":"12","author":"Bele\u00f9","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20220210-00280","article-title":"Grading of pancreatic neuroendocrine neoplasms with imaging: an update","volume":"102","author":"Miao","year":"2022","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.142224","article-title":"Can complementary 68Ga-DOTATATE and 18F-FDG PET\/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors","volume":"55","author":"Has Simsek","year":"2014","journal-title":"J Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112139-20210319-00135","article-title":"The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)","volume":"59","author":"Wu","year":"2021","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"14947","DOI":"10.1038\/s41598-023-41972-y","article-title":"Identification of a visualized web-based nomogram for overall survival prediction in patients with limited stage small cell lung cancer","volume":"13","author":"Liang","year":"2023","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.07.030","article-title":"Incidence of second Malignancy after successful treatment of limited-stage small-cell lung cancer and its effects on survival","volume":"12","author":"Kono","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.03.022","article-title":"Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma","volume":"42","author":"Long","year":"2019","journal-title":"EBioMedicine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312268","article-title":"Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma","volume":"66","author":"Bollard","year":"2017","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/17434440.2022.2141111","article-title":"Long axial field-of-view PET\/CT devices: are we ready for the technological revolution","volume":"19","author":"Filippi","year":"2022","journal-title":"Expert Rev Med Devices"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020426","article-title":"Advantages and applications of total-body PET scanning","volume":"12","author":"Katal","year":"2022","journal-title":"Diagnostics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1403260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T05:04:32Z","timestamp":1729055072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1403260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":28,"alternative-id":["10.3389\/fonc.2024.1403260"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1403260","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"article-number":"1403260"}}